McGinnity E S, Pluth T E
Ronning Management Group, Inc., Denver, CO.
Hosp Technol Ser. 1994 Jun;13(8):1-25.
High-cost, high-volume specialty programs such as orthopedics and neurosciences find themselves in a position of evaluating the costs and in some cases the appropriateness of medical practices in response to payer scrutiny and provider selection processes. Orthopedics and neurosciences programs are at a stage of development analogous to that of cardiovascular care several years ago. Many of the same trends have come into play, such as payer "carve-outs" for orthopedic services, payer selection of centers of excellence based on cost and quality, reduction of Medicare reimbursement, greater use of high-cost technology, the decline of profitability due to "older, sicker, and tougher" patients, and the recent emergence of national orthopedic specialty networks oriented to national contracts for care. In an era in which payers demand value on both sides of the cost-plus-quality equation, programs are challenged to maximize the return on a patient population rife with "no-win" situations. In the orthopedic service line these include a high proportion of Medicare patients and chronic conditions such as workers' compensation medical back cases or repetitive motion injuries, which can be elusive to diagnose and expensive to treat. Many hospitals continue to lose money on joint replacement surgeries, the largest-volume orthopedic inpatient service, primarily because of the high Medicare population and the cost of implants. Neuroservices, while still relatively well reimbursed, face a rising proportion of Medicare payments as patients live longer and develop chronic, degenerative conditions. Inpatient days are decreasing due to payer pressures to limit hospital stays and to shift inpatient care to outpatient services. Some hospitals "have lost interest in (the orthopedic) service line during the last five years because of recent trends in orthopedic-related inpatient volume and payment." But by managing costs strategically, both the neurosciences and orthopedics service lines can provide substantial revenue as well as the opportunity to achieve a "center of excellence" competitive position in a managed care environment. This Special Report outlines the process and advantages of managing costs and quality of care strategically, that is, in a manner which helps these programs meet internal cost and clinical goals while responding to market situations. The hospital, physicians, and patients all benefit as costs are reduced, quality is enhanced, and the service line's competitive position is strengthened.
诸如骨科和神经科学等成本高昂、业务量大的专科项目发现自己正处于这样一种境地:为应对付款方的审查和医疗服务提供者的选择过程,需要对成本进行评估,在某些情况下还要评估医疗实践的合理性。骨科和神经科学项目正处于一个类似于几年前心血管护理的发展阶段。许多相同的趋势开始发挥作用,比如付款方对骨科服务的“分拆”、付款方基于成本和质量选择卓越中心、医疗保险报销的减少、高成本技术的更多使用、由于“年龄更大、病情更重、治疗更难”的患者导致盈利能力下降,以及最近出现的面向全国护理合同的全国性骨科专科网络。在一个付款方在成本加质量等式的两边都要求价值的时代,这些项目面临着挑战,要在充满“必输”局面的患者群体中实现收益最大化。在骨科服务领域,这些情况包括高比例的医疗保险患者以及诸如工伤医疗背部病例或重复性运动损伤等慢性病况,这些病症难以诊断且治疗费用高昂。许多医院在关节置换手术(骨科最大量的住院服务项目)上持续亏损,主要原因是医疗保险患者比例高以及植入物成本高。神经科学服务虽然报销情况仍然相对良好,但随着患者寿命延长并出现慢性退行性疾病,医疗保险支付的比例在上升。由于付款方施加压力限制住院时间并将住院护理转向门诊服务,住院天数在减少。“由于骨科相关住院量和支付的近期趋势,一些医院在过去五年里对(骨科)服务领域失去了兴趣。” 但通过战略性地管理成本,神经科学和骨科服务领域都可以提供可观的收入,并有机会在管理式医疗环境中获得 “卓越中心” 的竞争地位。本特别报告概述了战略性地管理成本和护理质量的过程及优势,即采用一种有助于这些项目在应对市场情况的同时实现内部成本和临床目标的方式。随着成本降低、质量提高以及服务领域的竞争地位得到加强,医院、医生和患者都将受益。